Daiichi Sankyo sales and marketing update

Daiichi launched once-daily oral Savaysa edoxaban in the U.S. to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) and to treat deep vein thrombos...